Dechra Pharmaceuticals
British-founded veterinary pharmaceutical company developing and marketing medicines for companion animals, horses, and food-producing animals.
Last updated August 31, 2026
AI crawler reads
1requests
1companies- ByteDance1
- Profile
- 1
- Controversies
- 0
- JSON · MD
- 0
- First read
- Oct 30, 2026
- Latest read
- Oct 30, 2026
Since Oct 28, 2026 · from this site's server log
Overview
Dechra Pharmaceuticals is a veterinary pharmaceutical company founded in the United Kingdom and focused on the development, manufacture, and marketing of medicines and related products for animals. Its portfolio serves companion animals, particularly dogs and cats, as well as horses and food-producing animals. The business is associated with prescription veterinary products used in areas such as endocrine disease, dermatology, pain management, anaesthesia, and other chronic or acute conditions. The company originated in 1997 through a management buy-out from Lloyds Chemists. It subsequently developed from a UK-based veterinary-products business into an international animal-health group, expanding through public-market access, acquisitions, product development, and geographic growth. Dechra was admitted to the London Stock Exchange in 2000, giving it a listed platform for financing expansion and increasing its visibility within the veterinary pharmaceutical sector. A significant stage in its international development came in 2007, when Dechra acquired VetXX, a Danish veterinary-products company. The transaction strengthened the group’s European presence and broadened its product base. In 2010, Dechra added two further businesses: Florida-based DermaPet, which brought additional expertise in veterinary dermatology, and Sussex-based Genitrix. These acquisitions complemented Dechra’s existing product-development and commercial capabilities. Dechra also operated a veterinary-services business for part of its history. In July 2013, it sold that business to the United States company Patterson Companies for £87.5 million. The disposal reflected a strategic decision to concentrate on the higher-margin manufacturing and pharmaceutical side of the organization rather than retain a broader services model. Its best-known offerings include Vetoryl, used in the management of hyperadrenocorticism, commonly called Cushing’s disease, in dogs, and Felimazole, used to treat feline hyperthyroidism. The company’s commercial organization has been described in two principal regional divisions: European Pharmaceuticals and U.S. Pharmaceuticals. This structure reflects its international customer base and the different regulatory, distribution, and prescribing environments in major veterinary markets. In 2023, EQT AB agreed to acquire Dechra in a transaction valuing the company at approximately £4.5 billion. Regulatory and antitrust clearances were reported as obtained in December 2023, and completion was scheduled for 16 January 2024. The acquisition ended Dechra’s period as a London-listed company and transferred ownership to the private-equity group. The reference material further reports that Dechra moved its global headquarters to Boston, Massachusetts, in June 2026. Dechra therefore represents a British-origin veterinary-pharmaceutical brand with an international operating footprint and a strategic emphasis on specialized animal medicines.
History
Dechra Pharmaceuticals was established in 1997 through a management buy-out from Lloyds Chemists. From its origin as a British veterinary-products business, it pursued a growth strategy based on veterinary pharmaceutical development, commercialization, acquisitions, and international expansion. The company’s core markets included medicines for dogs, cats, horses, and food-producing animals. The business became publicly listed on the London Stock Exchange in 2000. Listing provided Dechra with a capital-market presence during a period in which the animal-health sector was becoming increasingly specialized and international. Rather than compete as a general human-pharmaceutical company, Dechra built its identity around veterinary medicines and products addressing specific clinical needs in animal health. In 2007, Dechra acquired VetXX, a Danish veterinary-products company, for £62 million. The purchase strengthened Dechra’s position in Europe and added to its portfolio and commercial infrastructure. Three years later, in 2010, Dechra acquired DermaPet in Florida for US$64 million and Genitrix in Sussex for £5 million. DermaPet was relevant to veterinary dermatology, while the Genitrix transaction added another UK-based veterinary-products business. Together, these acquisitions helped broaden the company’s geographic reach and therapeutic offering. Dechra later refined its business scope. In July 2013, it sold its veterinary-services business to Patterson Companies, a United States-based company, for £87.5 million. The sale was presented as a strategic move to concentrate on higher-margin manufacturing and pharmaceutical operations. This decision sharpened Dechra’s profile as a veterinary-drug developer and marketer rather than a diversified veterinary-services group. The company’s product portfolio included medicines for common conditions affecting companion and other animals. Vetoryl became a notable product for the management of canine Cushing’s disease, while Felimazole addressed hyperthyroidism in cats. Dechra’s operations were organized around European Pharmaceuticals and U.S. Pharmaceuticals, reflecting the importance of these regions and the need to operate across distinct regulatory and commercial systems. In June 2023, EQT AB made an agreed offer for Dechra. The proposed transaction valued the company at approximately £4.5 billion. By December 2023, the required antitrust and regulatory approvals had reportedly been secured. Completion was scheduled for 16 January 2024, after which Dechra ceased to be a London-listed company and became owned by EQT. The supplied reference material states that Dechra moved its global headquarters to Boston, Massachusetts, in June 2026. On that basis, the company’s current identity combines British origins, international veterinary-pharmaceutical operations, and ownership by EQT. Its historical development is marked by a progression from management-buy-out origins, through public listing and targeted acquisitions, to strategic concentration on pharmaceuticals and eventual take-private ownership.
- 2026
Reported global headquarters move
[1]The reference material reports that Dechra moved its global headquarters to Boston, Massachusetts, in June 2026.
- 2024
Planned completion of EQT transaction
[1]The EQT acquisition was scheduled to complete on 16 January 2024, taking Dechra off the London Stock Exchange.
- 2023
Agreed EQT takeover
[1]EQT AB agreed to acquire Dechra in a transaction valued at approximately £4.5 billion.
- 2013
Veterinary-services disposal
[1]Dechra sold its veterinary-services business to Patterson Companies for £87.5 million and redirected its focus toward manufacturing and pharmaceuticals.
- 2010
DermaPet and Genitrix acquisitions
[1]Dechra expanded through acquisitions of DermaPet in Florida and Genitrix in Sussex.
- 2007
VetXX acquisition
[1]The company acquired Danish veterinary-products business VetXX for £62 million.
- 2000
London Stock Exchange listing
[1]Dechra became a publicly listed company on the London Stock Exchange.
- 1997
Management buy-out establishes Dechra
[1]Dechra was formed through a management buy-out from Lloyds Chemists.
Products and positioning
A specialized international animal-health company focused on prescription veterinary medicines and differentiated products for companion animals, horses, and food-producing animals.
Canine endocrine medicine
Vetoryl
Vetoryl is a veterinary medicine used in the management of hyperadrenocorticism, commonly known as Cushing’s disease, in dogs. It is one of Dechra’s best-known companion-animal products and illustrates the company’s emphasis on specialized prescription treatments for chronic veterinary conditions.
Feline endocrine medicine
Felimazole
Felimazole is a veterinary medicine used to treat hyperthyroidism in cats. The product is part of Dechra’s companion-animal portfolio and addresses a common endocrine disorder in an aging feline population.
Veterinary dermatology · 2010
Veterinary dermatology products
Dechra’s dermatology offering was strengthened by the 2010 acquisition of DermaPet, a Florida-based veterinary-products business. The dermatology portfolio supports treatment and management of skin-related conditions in animals, although the supplied reference does not enumerate individual products.
Brand decisions
2023
Agreed acquisition by EQT ABM&ABackground
EQT AB proposed taking Dechra private after the company had operated as a London-listed veterinary-pharmaceutical group.
Action taken
Dechra agreed to EQT’s takeover offer, which valued the company at approximately £4.5 billion.
Aftermath
Following regulatory clearances and scheduled completion in January 2024, Dechra ceased to be listed on the London Stock Exchange and came under EQT ownership.
Transaction valuation. Approximately £4.5 billion (June 2023 agreed offer)
2013
Concentration on pharmaceutical manufacturingStrategyBackground
Dechra operated both veterinary services and pharmaceutical activities, but identified its manufacturing and pharmaceutical operations as higher-margin areas.
Action taken
The company sold its veterinary-services business to Patterson Companies for £87.5 million in July 2013.
Aftermath
The disposal narrowed Dechra’s strategic focus toward veterinary medicines and related manufacturing activities.
Sale consideration. £87.5 million (July 2013)
Recent events
- Unconfirmed
Dechra completes acquisition of worldwide Osurnia rights[2]
Reported:
Dechra Pharmaceuticals completed its acquisition of the worldwide rights to the Osurnia product portfolio from Elanco Animal Health for USD 135.0 million (£104.7 million).
Dechra agrees to acquire worldwide rights to Osurnia[3]
Reported:
Dechra announced that it had agreed terms to acquire the worldwide rights to Elanco's Osurnia product portfolio for USD 135.0 million. Completion was expected before the end of June 2020, subject to conditions and regulatory approvals.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/dechra-pharmaceuticals · Editorial policy · How profiles are compiled